
Andrew K Mcpherson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1715247/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|--------|-----------|
| 1 | Click chemistry in materials synthesis. 1. Adhesive polymers from copper-catalyzed azide-alkyne cycloaddition. Journal of Polymer Science Part A, 2004, 42, 4392-4403. | 2.3 | 394 |
| 2 | Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration. Journal of Medicinal Chemistry, 2008, 51, 1546-1559. | 6.4 | 46 |
| 3 | Inhibitors of ABL and the ABL-T315I Mutation. Current Topics in Medicinal Chemistry, 2008, 8, 905-921. | 2.1 | 42 |
| 4 | Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine—a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 602-608. | 2.2 | 41 |
| 5 | Discovery and preliminary structure–activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5546-5550. | 2.2 | 26 |
| 6 | The design and preliminary structure–activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5812-5818. | 2.2 | 23 |
| 7 | Synthesis of 5′-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies. Molecules, 2017, 22, 1356. | 3.8 | 23 |
| 8 | Formation of the N2-acetyl-2,6-diaminopurine oligonucleotide impurity caused by acetyl capping. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3243-3246. | 2.2 | 21 |
| 9 | Metabolism and Pharmacokinetics of a Novel Src Kinase Inhibitor 1G100435 ([7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and Its Active N-Oxide Metabolite TG100855 ([7-(2,6-Dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine). | 3.3 | 14 |
| 10 | Conversion of adenine to 5-amino-4-pyrimidinylimidazole caused by acetyl capping during solid phase oligonucleotide synthesis. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3468-3471. | 2.2 | 12 |
| 11 | Perspectives on the Designation of Oligonucleotide Starting Materials. Nucleic Acid Therapeutics, 2021, 31, 93-113. | 3.6 | 10 |
| 12 | Development of novel benzotriazines for drug discovery. Expert Opinion on Drug Discovery, 2009, 4, 33-49. | 5.0 | 9 |
| 13 | An Improved Process for the Manufacture of 5′- <i>O</i> -(4,4′-Dimethoxytrityl)- <i>N</i> ² -isobutyryl-2′- <i>O</i> -(2-methoxyethyl)guanos Organic Process Research and Development, 2020, 24, 2583-2590. | sin2e7 | 2 |
| 14 | Impurity Qualification Toxicology Study for a 2′-O-Methoxyethyl-Modified Antisense Inhibitor in Mice. Nucleic Acid Therapeutics, 2020, 30, 14-21. | 3.6 | 0 |